AB Science Announces Upcoming Live Webcast
AB Science SA is set to hold a live webcast, scheduled for a Monday evening. This event is aimed at sharing essential updates concerning their innovative drug development efforts, particularly focusing on the progress of two key platforms: masitinib and AB8939.
Agenda Highlights for the Webcast
The live webcast will take place over the course of an hour and will feature several notable professionals in the field. Attendees can look forward to insights directly from Alain Moussy, co-founder and CEO of AB Science, who will share the company’s vision, and Olivier Hermine, MD, PhD, who heads the Hematological department at Necker-Enfants Malades hospital.
Key Participants
The presence of leading figures who are deeply involved in the development of groundbreaking therapies will bring significant value to the event. Participants will be discussing the implications of recent research and potential future applications of their drug platforms.
Accessing the Webcast
For those interested in joining this informative session, details to access the webcast include the date, which coincides with the aforementioned Monday evening, and the corresponding timing across geographical regions: 11:30 AM to 12:30 PM ET in the US and 5:30 PM to 6:30 PM CET in Europe.
How to Join the Webcast
Participants will be able to join via a dedicated platform where an audio stream along with a presentation will be available. This setup aims to foster interaction and engagement, allowing participants to gain a robust understanding of AB Science's developments.
About AB Science
Founded in 2001, AB Science is a pharmaceutical company dedicated to the research, development, and marketing of protein kinase inhibitors (PKIs). This class of drugs plays a crucial role in various cellular signaling pathways and targets diseases with significant unmet medical needs, often in severe and life-threatening conditions.
Innovations and Developments
AB Science is proud of its proprietary portfolio of PKIs. The lead compound, masitinib, has already received registration for use in veterinary medicine and is currently being advanced in human medicine across oncology, neurological disorders, inflammatory conditions, and certain viral diseases.
Executive Summary
The webcast represents an essential opportunity for stakeholders to gain firsthand insights into AB Science's ongoing projects and objectives. It serves not just to inform but also to engage with the community about their innovative therapeutic strategies.
Future Prospects
As AB Science continues to push the boundaries of medical research and development, their initiatives highlight a commitment to addressing substantial health challenges. By focusing on diseases that have traditionally lacked effective treatment options, they hope to make a meaningful impact on patient care.
Frequently Asked Questions
When is the AB Science webcast scheduled to take place?
The webcast is scheduled for a Monday evening, from 5:30 PM to 6:30 PM CET.
Who are the main speakers at the live webcast?
The main speakers include Alain Moussy, the CEO, and Olivier Hermine, a prominent medical doctor focused on hematological issues.
What topics will be covered during the webcast?
The webcast will provide updates on masitinib and AB8939 platforms, detailing recent developments and future directions for these therapies.
How can I access the webcast?
Participants can join the webcast via a dedicated Zoom link, which will feature audio and a presentation component.
What is the primary focus of AB Science?
AB Science focuses on developing and commercializing protein kinase inhibitors to treat significant medical conditions with unmet needs.
